CCNT2

Across TCGA pan-cancer cohorts, CCNT2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCNT2 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CCNT2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCNT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, UCEC, and LIHC are the cancer types where CCNT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.147	0.630	.004	12	view →
UCEC	DFS	Median	All	0.965	0.624	.012	10	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
LUAD	DFS	Median	All	0.339	0.667	.025	3	view →
SKCM	DFS	Median	II,III,IV	0.192	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCNT2–KIRC (OS)

Open the KIRC breakdown →